BMO Capital Sees Potential Best-In-Class EGFRv111 Antibody from Affimed Therapeutics (AFMD)
Tweet Send to a Friend
BMO Capital analyst Jim Birchenough reiterated an Outperform rating and $13 price target on Affimed Therapeutics (NASDAQ: AFMD) saying a ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
